Locnartecan

DB16186InvestigationalSmall molecule

PEN-866 is under investigation in clinical trial NCT03221400 (PEN-866 in Patients With Advanced Solid Malignancies).

Chemical structure of Locnartecan
Formula / weight
C49H49N7O9 · 879.971 g/mol (avg)
Also known as
Hsp90-targeted sn-38 conjugate pen-866
Code names
HDC SN-38 · PEN-866 · STA 12-8666

Resolves to

Compound
UNII56DL1J49LRCAS1472614-83-7ChEMBLCHEMBL4297475
Structure
InChIKeyQTPZAEAYDWMVJO-GGCSAXROSA-NSMILESCCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CCN4C=CC5=CC(=CC=C45)N4C(=O)NN=C4C4=CC(C(C)C)=C(O)C=C4O)CC3)C=C12
Targets
P11387TOP1

What you can answer from here — as of October 27, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with Locnartecan, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In